283 related articles for article (PubMed ID: 27063095)
1. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
Li Z; Zhu Q; Chen H; Hu L; Negi H; Zheng Y; Ahmed Y; Wu Z; Li D
Cancer Lett; 2016 Jul; 377(1):32-43. PubMed ID: 27063095
[TBL] [Abstract][Full Text] [Related]
2. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
[TBL] [Abstract][Full Text] [Related]
3. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
[TBL] [Abstract][Full Text] [Related]
4. Induction of anterior gradient 2 (AGR2) plays a key role in insulin-like growth factor-1 (IGF-1)-induced breast cancer cell proliferation and migration.
Li Z; Wu Z; Chen H; Zhu Q; Gao G; Hu L; Negi H; Kamle S; Li D
Med Oncol; 2015 Jun; 32(6):577. PubMed ID: 25956506
[TBL] [Abstract][Full Text] [Related]
5. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.
Wright TM; Wardell SE; Jasper JS; Stice JP; Safi R; Nelson ER; McDonnell DP
Mol Cancer Res; 2014 Dec; 12(12):1829-39. PubMed ID: 25100862
[TBL] [Abstract][Full Text] [Related]
6. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
[TBL] [Abstract][Full Text] [Related]
7. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
8. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
10. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Fox EM; Miller TW; Balko JM; Kuba MG; Sánchez V; Smith RA; Liu S; González-Angulo AM; Mills GB; Ye F; Shyr Y; Manning HC; Buck E; Arteaga CL
Cancer Res; 2011 Nov; 71(21):6773-84. PubMed ID: 21908557
[TBL] [Abstract][Full Text] [Related]
11. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
Song RX; Chen Y; Zhang Z; Bao Y; Yue W; Wang JP; Fan P; Santen RJ
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):219-30. PubMed ID: 19815064
[TBL] [Abstract][Full Text] [Related]
12. Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
Zimmermann M; Arachchige-Don AP; Donaldson MS; Patriarchi T; Horne MC
Cell Cycle; 2016 Dec; 15(23):3278-3295. PubMed ID: 27753529
[TBL] [Abstract][Full Text] [Related]
13. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor.
Khalid S; Hanif R; Jabeen I; Mansoor Q; Ismail M
PLoS One; 2018; 13(5):e0196312. PubMed ID: 29787591
[TBL] [Abstract][Full Text] [Related]
15. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
Antoon JW; Martin EC; Lai R; Salvo VA; Tang Y; Nitzchke AM; Elliott S; Nam SY; Xiong W; Rhodes LV; Collins-Burow B; David O; Wang G; Shan B; Beckman BS; Nephew KP; Burow ME
PLoS One; 2013; 8(8):e69291. PubMed ID: 23950888
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
Zhang X; Diaz MR; Yee D
Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.
Yu L; Wang L; Mao C; Duraki D; Kim JE; Huang R; Helferich WG; Nelson ER; Park BH; Shapiro DJ
Cancer Lett; 2019 Feb; 442():373-382. PubMed ID: 30419347
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
19. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
Fukui F; Hayashi SI; Yamaguchi Y
J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
Ishii Y; Papa L; Bahadur U; Yue Z; Aguirre-Ghiso J; Shioda T; Waxman S; Germain D
Clin Cancer Res; 2011 Apr; 17(8):2292-300. PubMed ID: 21292820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
